{"@id":"https://bioecon.ru/technology/geroprotector-repurposing-rapamycin-metformin-tame/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://bioecon.ru/technology/geroprotector-repurposing-rapamycin-metformin-tame/","json":"https://bioecon.ru/api/v1/technology/geroprotector-repurposing-rapamycin-metformin-tame/index.json"},"id":"geroprotector-repurposing-rapamycin-metformin-tame","industries":["longevity"],"lang":"ru","links":{"industries":["https://bioecon.ru/industries/longevity/"],"suppliers":["https://bioecon.ru/companies/vinaseed/","https://bioecon.ru/companies/milwhite-inc/","https://bioecon.ru/companies/bioviva/","https://bioecon.ru/companies/pivot-bio/","https://bioecon.ru/companies/mustgrow-biologics-corp/"]},"maturity":4,"name":"Испытания перепрофилирования геропротекторов (рапамицин, метформин, TAME)","regions":["us","eu"],"risk":"high","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-09","entity":"onlinelibrary.wiley.com","kind":"research","urls":["https://onlinelibrary.wiley.com/doi/10.1111/acel.13596"]},{"date":"2026-11-09","entity":"pmc.ncbi.nlm.nih.gov","kind":"research","urls":["https://pmc.ncbi.nlm.nih.gov/articles/PMC6428447/","https://pmc.ncbi.nlm.nih.gov/articles/PMC5055653/","https://pmc.ncbi.nlm.nih.gov/articles/PMC12486172/"]},{"date":"2026-11-09","entity":"ncbi.nlm.nih.gov","kind":"research","urls":["https://ncbi.nlm.nih.gov/pmc/articles/PMC10643772/"]}],"stages":[{"n":1,"title":"Диалог с регулятором"},{"n":2,"title":"Дизайн испытания"},{"n":3,"title":"Отбор кандидатов"},{"n":4,"title":"Конечная точка"}],"summary":"Одобренные препараты проверяют как средства против старения; испытание TAME с метформином запланировано, рапамицин в ранних испытаниях, а FDA и EMA пока не признают исходы старения основанием для одобрения.","url":"/technology/geroprotector-repurposing-rapamycin-metformin-tame/","verified":"2026-11-09"}